All News
Lupus Nephritis 2024 Guidelines
The ACR has published evidence-based and expert guidance for the screening, treatment, and management of lupus nephritis (LN). These are the same guidelines presented at ACR Convergence 2024.
Read Article
Assessing and Treating CV Risk Increases in Systemic Lupus
We’ve recognized the increased risk of cardiovascular disease (CVD) in SLE for almost half a century since Urowitz et al. first described a bimodal pattern of mortality in lupus patients in 1976. Numerous subsequent studies have confirmed this, with estimates of increased risk ranging from 2-10-fold compared to the general population. Most striking is the risk in young patients; in their landmark study, Manzi et al. found that women with SLE in the 35–44-year age group had an almost 50-fold increased risk of myocardial infarction compared to age-matched women without SLE.
Read Article
Lupus in an empty house
The full house immunofluorescence pattern is the classic histopathologic finding of lupus and lupus nephritis. Glomerular deposits staining for IgG, IgA, IgM, C3 and C1q can help confirm a suspected diagnosis of SLE. But what about patients with negative immunofluorescence and no proliferative or membranous features?
Read Article
Refractory Renal SLE
How to manage class III/IV lupus glomerulonephritis when you run out of options, by Dr. Jack Cush.
https://t.co/syOVCEozfA https://t.co/UOY8MkZeX2
Dr. John Cush RheumNow ( View Tweet)
Lessons Learned from a Lupus Registry: Two sides of one coin?
It's Dr. Janet Pope reporting at RheumNow on our special lupus edition. I'd like to talk about lessons learned from a Canadian lupus registry. Is it two sides of one coin?
https://t.co/IxMZhA1uht https://t.co/PJixCj8d6g
Dr. John Cush RheumNow ( View Tweet)
J&J announced results of Phase 3 ICONIC-TOTAL study of qd icotrokinra, an oral IL-23 receptor inhibitor, in 311 ps w/ difficult scalp and genital psoriasis (PSO) -success in 57%; skin clearance in 66% & genital psoriasis resp in 77% treated https://t.co/WftyEcDh8u https://t.co/Ydy37Eo0jX
Dr. John Cush RheumNow ( View Tweet)
CDC: U.S. Overdose Deaths Decrease Almost 27% in 2024, dropping from 110,037 deaths (2023) to ~80,391(2024). Despite these improvements, overdose remains the leading cause of death for Americans aged 18 to 44. https://t.co/UXTaOPf3P7 https://t.co/1NQUfoZ1eK
Links:
Dr. John Cush RheumNow ( View Tweet)
Single center study of 2741 ANA tests: 65% ANA negative, 31% ANA+ w/ nuclear staining patterns, & 2.0% ANA+ w cytoplasmic staining. Cytoplasmic - most were reticular, dense fine speckled next. Reticular assoc w/ primary biliary cholangitis (w/ Abs against M2). Dense fine https://t.co/JI7iGvw8xp
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Refractory Renal SLE
How to manage class III/IV lupus glomerulonephritis when you run out of options
Features Dr. Jack Cush.
https://t.co/8CQm8GZ213 https://t.co/lJKvcpIq60
Dr. John Cush RheumNow ( View Tweet)
QOL survey of on 5222 lupus pts (94% F; 56% both CLE/SLE; 40% w/ SLE. QOL concerns on social activities (60%), mental health (38%). CLE had increased therapeutic hesitancy and less likely to believe in the efficacy of biologics than SLE or both. https://t.co/BOUXUSmmcM https://t.co/62Z1aFsbbv
Dr. John Cush RheumNow ( View Tweet)
#2 most downloaded paper in 2024 on Journal of Clinical Medicine was “IgA Vasculitis (Henoch–Schönlein Purpura): An Update on Treatment” - Steroids are 1st line Rx, esp in adults w/ severe IgAV; other Rx include calcineurin inhibitors, MMF, RTX , https://t.co/F5jogxkoGr
Dr. John Cush RheumNow ( View Tweet)
National Inpatient Sample retrospective study of #RA pts using cannabis (n 42,415). Cannabis assoc w/ lower mortality (0.98% vs 2.71%; OR 0.50), depression (OR 0.47), chronic pain (OR 0.45), anxiety (OR 0.55); but more use of opioids (OR: 1.10), nicotine (OR: 1.35), & alcohol https://t.co/87SnCHVxkN
Dr. John Cush RheumNow ( View Tweet)
Is the nosology of CPPD outdated? Pseudogout to chondrocalcinosis? In 2011 EULAR taskforce rec the preferred term "calcium pyrophosphate deposition dz". G-CAN aims to update & standardised terminology for CPPD, requiring change to ICD-10 & adoption by societies https://t.co/mdqwDQN1po
Dr. John Cush RheumNow ( View Tweet)
Soluble CD13 (sCD13) has pro-inflammatory effects & is elevated in severe COVID-19. sCD13 is chemotactic, angiogenic, & arthritogenic. In COVID-19, sCD13 was assoc w/ sCD13 severity, ethnicity, inflammation markers, NETosis, & vascular injury/thrombosis. https://t.co/2bKY9NtnCD
Dr. John Cush RheumNow ( View Tweet)
Comparing EULAR (2025) and ACR (2020) Guidelines on Safety of Lupus Medications in Pregnancy
Attendees at the 2025 RheumaPreg meeting were excited to discuss the newly released EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation. https://t.co/DSYPaElRij
Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study 112 biopsy-proven Lupus nephritis pts (65% class IV; F/U 8.3 yrs). (64.3%), alone or in combination. Renal damage incr betw 5 & 10 yrs F/U. 13.4% progressed to renal function impairment, and 11.6% to ESRD. Early Dx & Rx of LN, esp w/ highproteinuria, https://t.co/yHzN1Hczb4
Dr. John Cush RheumNow ( View Tweet)
A brief history of familial Mediterranean fever - FMF is most common periodic fever syndr. an inherited polyserositis mainly affects Arabs, Armenians, Jews, & Turks. Hx may date back to 1802 & Heberden. Osler described 11 cases in 1895. 1st clear report 1945 by Siegal 10 pts. https://t.co/61WOxt9fPy
Dr. John Cush RheumNow ( View Tweet)
QOL survey of on 5222 lupus pts (94% F; 56% both CLE/SLE; 40% w/ SLE. QOL concerns on social activities (60%), mental health (38%). CLE had increased therapeutic hesitancy and less likely to believe in the efficacy of biologics than SLE or both. https://t.co/BOUXUSmmcM https://t.co/zrzEsDDqVn
Dr. John Cush RheumNow ( View Tweet)
#2 most downloaded paper in 2024 on Journal of Clinical Medicine was “IgA Vasculitis (Henoch–Schönlein Purpura): An Update on Treatment” - Steroids are 1st line Rx, esp in adults w/ severe IgAV; other Rx include calcineurin inhibitors, MMF, RTX , https://t.co/F5jogxkoGr
Dr. John Cush RheumNow ( View Tweet)
Full read overview of Discoid Lupus. https://t.co/G6lXWTRSFn https://t.co/yjVsDg0D5d
Links:
Dr. John Cush RheumNow ( View Tweet)